Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that reduces gastric acid production.
## Primary Indications
* Healing of erosive esophagitis
* Gastroesophageal reflux disease (GERD)
* Reduction of risk of NSAID-associated gastric ulcers
* Pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome)
## Adult Dosing
* **Erosive Esophagitis:** 40 mg once daily for up to 8 weeks. A second 8-week course may be considered for patients not healed after the initial treatment.
* **GERD:** 20 mg to 40 mg once daily. For maintenance of healing of erosive esophagitis or reduction of symptoms of GERD, 20 mg once daily may be sufficient.
* **NSAID-Associated Ulcers:** 40 mg once daily. Duration is typically up to 8 weeks.
* **Pathological Hypersecretory Conditions:** Starting dose is 40 mg twice daily. Doses may be adjusted based on clinical response, with doses up to 240 mg daily (divided into two doses) reported.
## Pediatric Dosing
* **1-5 years (weighing 15-40 kg):** 20 mg once daily for up to 8 weeks for GERD.
* **6-11 years (weighing 40-50 kg):** 40 mg once daily for up to 8 weeks for GERD.
* **6-11 years (weighing < 40 kg):** 20 mg once daily for up to 8 weeks for GERD.
* **12-17 years:** 40 mg once daily for up to 8 weeks for GERD and erosive esophagitis.
*Note: Dosing for pediatric patients may vary based on specific indication and local protocols. Consult pediatric guidelines.*
## Dose Adjustments
No dose adjustment is generally required for patients with hepatic or renal impairment, though caution may be advised in severe hepatic impairment.
## Contraindications
* Known hypersensitivity to pantoprazole, any component of the formulation, or other substituted benzimidazoles.
## Adverse Effects
Common: Headache, diarrhea, nausea, abdominal pain, flatulence, dizziness.
Serious:
* Fracture of hip, wrist, or spine (associated with prolonged PPI use)
* *Clostridium difficile*-associated diarrhea
* Vitamin B12 deficiency
* Hypomagnesemia (can be severe)
* Cutaneous and systemic lupus erythematosus
## Key Drug Interactions
* **Warfarin:** May increase INR and prothrombin time. Monitor INR closely.
* **Methotrexate:** PPIs may increase methotrexate levels, leading to toxicity. Consider PPI discontinuation or methotrexate dose reduction if clinically indicated.
* **Drugs dependent on gastric pH for absorption:** PPIs can decrease absorption of drugs like ketoconazole, itraconazole, posaconazole, erlotinib, and certain HIV protease inhibitors (e.g., atazanavir, ritonavir).
* **CYP2C19 Substrates:** Pantoprazole inhibits CYP2C19. Caution with substrates like clopidogrel, citalopram, and diazepam.
## Monitoring
* Monitor for adverse effects, especially with prolonged use (fractures, *C. difficile*, B12 deficiency, hypomagnesemia).
* Consider magnesium levels, especially in patients on other medications that can cause hypomagnesemia or those on long-term PPI therapy.
## Clinical Pearls
* Pantoprazole is available as delayed-release tablets and for intravenous administration.
* Administer delayed-release tablets at least 1 hour before a meal.
* IV formulation should be administered slowly over at least 2 minutes.
* Long-term PPI use can increase the risk of certain adverse events; use the lowest effective dose for the shortest duration necessary.
***
**Disclaimer:** This information is intended for healthcare professionals and is not a substitute for professional medical advice. Always consult current prescribing information and relevant guidelines before making any treatment decisions.
